| Drug Name |
Eletriptan hydrobromide |
| Drug ID |
BADD_D00756 |
| Description |
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches. |
| Indications and Usage |
For the acute treatment of migraine with or without aura in adults. |
| Marketing Status |
approved; investigational |
| ATC Code |
N02CC06 |
| DrugBank ID |
DB00216
|
| KEGG ID |
D01973
|
| MeSH ID |
C115647
|
| PubChem ID |
656631
|
| TTD Drug ID |
D02DMQ
|
| NDC Product Code |
65015-719; 65162-042; 59651-104; 27241-040; 59651-105; 55700-756; 59762-2322; 10829-0558; 48087-0090; 0378-4288; 65162-043; 68382-922; 70771-1107; 48087-0102; 63126-904; 65977-0059; 68382-923; 71335-1830; 59762-2321; 0049-2330; 0378-4287; 70771-1108; 0093-8311; 63629-8320; 0049-2340; 10829-0557; 59651-101; 0093-8310; 27241-039 |
| UNII |
M41W832TA3
|
| Synonyms |
eletriptan | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole | UK 166,044 | UK-166044 | UK 166044 | UK-166,044 | Relpax | UK-116044-04 | UK-116,044-04 | eletriptan hydrobromide | (R)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole monohydrobromide | 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide |
